Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motesanib in Advanced Thyroid Cancer
NCT00121628Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2005
- Primary completion
- Nov 2006
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of motesanib in thyroid cancer (2 arms), sponsored by Amgen. Primary endpoint: Objective Response Rate. Started Jul 2005; status: completed.
02
Drugs
motesanib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT00121628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121628.